UNICREDIT BANK/CALL/NOVO-NORDISK B/1600/0.1/19.03.25 | Market Closed - Börse Stuttgart 12:11:37 18/05/2024 am IST | ||
| 0.081 EUR | -14.74% |
|
| Current month | -26.36% | ||
| 1 month | -19.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 17/24/17 | 0.081 | -14.74% |
| 16/24/16 | 0.095 | -32.14% |
| 15/24/15 | 0.14 | +27.27% |
| 14/24/14 | 0.11 | 0.00% |
| 13/24/13 | 0.11 | +22.22% |
Delayed Quote Börse Stuttgart
Last update May 18, 2024 at 12:11 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD43LL |
| ISIN | DE000HD43LL8 |
| Date issued | 25/03/2024 |
| Strike | 1,600 kr |
| Maturity | 19/03/2025 (306 Days) |
| Parity | 10 : 1 |
| Emission price | 0.4 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.32 € |
|---|---|
| Lowest since issue | 0.045 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
903.3
DKK
Average target price
909.2
DKK
Spread / Average Target
+0.66%
- Stock Market
- Warrants
- Warrant
